Pregledni rad
Autologous stem cell transplantation in the treatment of non-Hodgkin’s lymphoma
Nadira Duraković
; Division of Hematology, Department of Internal Medicine, Clinical Hospital Center Zagreb, Croatia
Damir Nemet
; Division of Hematology, Department of Internal Medicine, Clinical Hospital Center Zagreb, Croatia
Sažetak
Substantial number of patients who present with non-Hodgkin’s lymphoma cannot be cured of their disease by conventional dose therapy. New data on treatment results in the past decade elucidate the role of high-dose therapy (HDT) and autologous bone marrow or peripheral blood stem cells in the treatment of malignant lymphomas. There is evidence from randomized studies that high-dose therapy followed by autografting for relapsed chemosensitive patients is superior to conventional chemotherapy in terms of disease-free and overall survival. For this group of patients autografting became a standard approach to therapy. Also the increasing evidences indicate that high-dose therapy and autotransplantation in first remission improves survival in high-risk patients. The toxicity of the procedure is substantially reduced in recent years. Several new methods are under investigation, like various forms of immunotherapy and radioimmunotherapy, with the aim to reduce the incidence of relapse following transplantation.
Ključne riječi
non-Hodgkin’s lymphoma, autotransplantation;
Hrčak ID:
280777
URI
Datum izdavanja:
22.11.2007.
Posjeta: 371 *